{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T02:23:18Z","timestamp":1776219798586,"version":"3.50.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T00:00:00Z","timestamp":1689552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T00:00:00Z","timestamp":1689552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Jagiellonian University School of Medicine","award":["K\/ZDS\/000565"],"award-info":[{"award-number":["K\/ZDS\/000565"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p> Type 2 diabetes mellitus (T2DM) patients are at high risk of cardiovascular (CV) events. Factor XI (FXI) is associated with arterial thromboembolism, including myocardial infarction (MI), stroke, and CV mortality. The role of FXI in T2DM is unknown. We investigated whether plasma FXI is associated with CV events in T2DM patients in long-term observation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In 133 T2DM patients (aged 66\u2009\u00b1\u20098 years, 40.6% women, median T2DM duration 5 [2\u201310] years) we assessed plasma FXI levels, along with fibrin clot properties, thrombin generation, and fibrinolysis proteins. A composite endpoint of MI, stroke, or CV death, as well as CV mortality alone were assessed during a median follow-up of 72 months.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Plasma FXI above the 120% upper normal limit was detected in 25 (18.8%) patients and showed positive association with LDL cholesterol and thrombin activatable fibrinolysis inhibitor, but not glycated hemoglobin, inflammatory markers or thrombin generation. The composite endpoint (n\u2009=\u200921, 15.8%) and CV death alone (n\u2009=\u200916, 12%) were more common in patients with elevated FXI (hazard ratio [HR] 10.94, 95% confidence interval [CI] 4.46\u201326.87, p\u2009&lt;\u20090.001 and HR 7.11, 95% CI 2.61\u201319.31, p\u2009&lt;\u20090.001, respectively). On multivariable analysis, FXI remained an independent predictor of the composite endpoint and CV death, regardless of concomitant coronary artery disease.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>To our knowledge, this study is the first to show that in T2DM patients, elevated FXI could predict major CV events, including mortality, which suggest that anti-FXI agents might be a potential novel antithrombotic option in this disease.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12933-023-01905-5","type":"journal-article","created":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T18:02:24Z","timestamp":1689616944000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Elevated plasma factor XI predicts cardiovascular events in patients with type 2 diabetes: a long-term observational study"],"prefix":"10.1186","volume":"22","author":[{"given":"El\u017cbieta","family":"Paszek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maciej","family":"Polak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agata Hanna","family":"Bryk-Wi\u0105zania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma\u0142gorzata","family":"Konieczy\u0144ska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anetta","family":"Undas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,17]]},"reference":[{"key":"1905_CR1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12933-022-01516-6","volume":"21","author":"CX Ma","year":"2022","unstructured":"Ma CX, Ma XN, Guan CH, Li YD, Mauricio D, Fu SB. Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management. Cardiovasc Diabetol. 2022;21:74. https:\/\/doi.org\/10.1186\/s12933-022-01516-6.","journal-title":"Cardiovasc Diabetol"},{"key":"1905_CR2","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1055\/s-0033-1343888","volume":"39","author":"O Morel","year":"2013","unstructured":"Morel O, Jesel L, Abbas M, Morel N. Prothrombotic changes in diabetes mellitus. Semin Thromb Hemost. 2013;39:477\u201388. https:\/\/doi.org\/10.1055\/s-0033-1343888.","journal-title":"Semin Thromb Hemost"},{"key":"1905_CR3","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1007\/s00125-005-1742-2","volume":"48","author":"EJ Dunn","year":"2005","unstructured":"Dunn EJ, Ari\u00ebns RS, Grant PJ. The influence of type 2 diabetes on fibrin structure and function. Diabetologia. 2005;48:1198\u2013206. https:\/\/doi.org\/10.1007\/s00125-005-1742-2.","journal-title":"Diabetologia"},{"key":"1905_CR4","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1160\/TH14-05-0468","volume":"112","author":"S Neergaard-Petersen","year":"2014","unstructured":"Neergaard-Petersen S, Hvas AM, Kristensen SD, Grove EL, Larsen SB, Phoenix F, et al. The influence of type 2 diabetes on fibrin clot properties in patients with coronary artery disease. Thromb Haemost. 2014;112:1142\u201350. https:\/\/doi.org\/10.1160\/TH14-05-0468.","journal-title":"Thromb Haemost"},{"key":"1905_CR5","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1160\/TH06-07-0390","volume":"96","author":"M Pieters","year":"2006","unstructured":"Pieters M, Covic N, Loots DT, van der Westhuizen FH, van Zyl DG, Rheeder P, et al. The effect of glycaemic control on fibrin network structure of type 2 diabetic subjects. Thromb Haemost. 2006;96:623\u20139.","journal-title":"Thromb Haemost"},{"key":"1905_CR6","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1182\/blood-2013-04-494641","volume":"122","author":"RA Ajjan","year":"2013","unstructured":"Ajjan RA, Gamlen T, Standeven KF, Mughal S, Hess K, Smith KA, et al. Diabetes is associated with posttranslational modifications in plasminogen resulting in reduced plasmin generation and enzyme-specific activity. Blood. 2013;122:134\u201342. https:\/\/doi.org\/10.1182\/blood-2013-04-494641.","journal-title":"Blood"},{"key":"1905_CR7","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1055\/s-0038-1676609","volume":"119","author":"AH Bryk","year":"2019","unstructured":"Bryk AH, Konieczynska M, Rostoff P, Broniatowska E, Hohendorff J, Malecki MT, et al. Plasma protein oxidation as a determinant of impaired fibrinolysis in type 2 diabetes. Thromb Haemost. 2019;119:213\u201322. https:\/\/doi.org\/10.1055\/s-0038-1676609.","journal-title":"Thromb Haemost"},{"key":"1905_CR8","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1161\/01.ATV.0000242905.41404.68","volume":"26","author":"MC Alessi","year":"2006","unstructured":"Alessi MC, Juhan-Vague I, Arteriosclerosis. Thromb Vascular Biology. 2006;26:2200\u20137. https:\/\/doi.org\/10.1161\/01.ATV.0000242905.41404.68.","journal-title":"Thromb Vascular Biology"},{"key":"1905_CR9","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1210\/jcem.87.2.8214","volume":"87","author":"Y Hori","year":"2002","unstructured":"Hori Y, Gabazza EC, Yano Y, Katsuki A, Suzuki K, Adachi Y, et al. Insulin resistance is associated with increased circulating level of thrombin-activatable fibrinolysis inhibitor in type 2 diabetic patients. J Clin Endocrinol Metab. 2002;87:660\u20135. https:\/\/doi.org\/10.1210\/jcem.87.2.8214.","journal-title":"J Clin Endocrinol Metab"},{"key":"1905_CR10","doi-asserted-by":"publisher","unstructured":"Dunn EJ, Philippou H, Ari\u00ebns RA, Grant PJ. Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus. Diabetologia 2006;49. https:\/\/doi.org\/10.1007\/s00125-006-0197-4.","DOI":"10.1007\/s00125-006-0197-4"},{"key":"1905_CR11","doi-asserted-by":"publisher","first-page":"16113","DOI":"10.20452\/pamw.16113","volume":"131","author":"JB Larsen","year":"2021","unstructured":"Larsen JB, Hvas A-M. Fibrin clot properties in coronary artery disease: new determinants and prognostic markers. Pol Arch Intern Med. 2021;131:16113. https:\/\/doi.org\/10.20452\/pamw.16113.","journal-title":"Pol Arch Intern Med"},{"key":"1905_CR12","doi-asserted-by":"publisher","first-page":"16358","DOI":"10.20452\/pamw.16358","volume":"132","author":"T Nowakowski","year":"2022","unstructured":"Nowakowski T, Batko K, Undas A. Denser fibrin clot networks in patients at high risk of recurrent arterial thromboembolism following acute limb ischemia of unknown cause. Pol Arch Intern Med. 2022;132:16358. https:\/\/doi.org\/10.20452\/pamw.16358.","journal-title":"Pol Arch Intern Med"},{"key":"1905_CR13","doi-asserted-by":"publisher","unstructured":"Bryk AH, Konieczy\u0144ska M, Polak M, Plicner D, Bochenek M, Undas A. Plasma fibrin clot properties and cardiovascular mortality in patients with type 2 diabetes: a long-term follow-up study. Cardiovasc Diabetol. 2021;20. https:\/\/doi.org\/10.1186\/s12933-021-01230-9.","DOI":"10.1186\/s12933-021-01230-9"},{"key":"1905_CR14","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1056\/NEJMra1011670","volume":"364","author":"JI Borissoff","year":"2011","unstructured":"Borissoff JI, Spronk HMH, ten Cate H. The hemostatic system as a modulator of atherosclerosis. N Engl J Med. 2011;364:1746\u201360. https:\/\/doi.org\/10.1056\/NEJMra1011670.","journal-title":"N Engl J Med"},{"key":"1905_CR15","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1055\/s-0040-1710013","volume":"120","author":"M Visser","year":"2020","unstructured":"Visser M, Heitmeier S, Ten Cate H, Spronk HMH. Role of factor XIa and plasma kallikrein in arterial and venous thrombosis. Thromb Haemost. 2020;120:883\u2013993. https:\/\/doi.org\/10.1055\/s-0040-1710013.","journal-title":"Thromb Haemost"},{"key":"1905_CR16","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1182\/blood-2016-09-742262","volume":"129","author":"M Preis","year":"2017","unstructured":"Preis M, Hirsch J, Kotler A, Zoabi A, Stein N, Rennert G, et al. Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events. Blood. 2017;129:1210\u20135. https:\/\/doi.org\/10.1182\/blood-2016-09-742262.","journal-title":"Blood"},{"key":"1905_CR17","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/s0021-9150(01)00666-9","volume":"161","author":"C Merlo","year":"2002","unstructured":"Merlo C, Wuillemin WA, Redondo M, Furlan M, Sulzer I, Kremer-Hovinga J, et al. Elevated levels of plasma prekallikrein, high molecular weight kininogen and factor XI in coronary heart disease. Atherosclerosis. 2002;161:261\u20137. https:\/\/doi.org\/10.1016\/s0021-9150(01)00666-9.","journal-title":"Atherosclerosis"},{"key":"1905_CR18","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1111\/jth.12531","volume":"12","author":"B Siegerink","year":"2014","unstructured":"Siegerink B, Rosendaal FR, Algra A. Antigen levels of coagulation factor XII, coagulation factor XI and prekallikrein, and the risk of myocardial infarction and ischemic stroke in young women. J Thromb Haemost. 2014;12:606\u201313. https:\/\/doi.org\/10.1111\/jth.12531.","journal-title":"J Thromb Haemost"},{"key":"1905_CR19","doi-asserted-by":"publisher","unstructured":"Paszek E, Malinowski KP, Z\u0105bczyk M, Butenas S, Undas A. Elevated factor XIa as a modulator of plasma fibrin clot properties in coronary artery disease. Eur J Clin Invest. 2023;e14007. https:\/\/doi.org\/10.1111\/eci.14007.","DOI":"10.1111\/eci.14007"},{"key":"1905_CR20","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.atherosclerosis.2022.02.009","volume":"346","author":"E Paszek","year":"2022","unstructured":"Paszek E, Pociask E, Z\u0105bczyk M, Pi\u00f3rkowski A, Butenas S, Legutko J, et al. Active factor XI is associated with the risk of cardiovascular events in stable coronary artery disease patients. Atherosclerosis. 2022;346:124\u201332. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.02.009.","journal-title":"Atherosclerosis"},{"key":"1905_CR21","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1055\/s-0042-1742366","volume":"122","author":"MT Z\u0105bczyk","year":"2022","unstructured":"Z\u0105bczyk MT, Hanarz M, Malinowski KP, Pociask E, Butenas S, Gajos G, et al. Active FXI can independently predict ischemic stroke in Anticoagulated Atrial Fibrillation Patients: a Cohort Study. Thromb Haemost. 2022;122:1397\u2013406. https:\/\/doi.org\/10.1055\/s-0042-1742366.","journal-title":"Thromb Haemost"},{"key":"1905_CR22","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1160\/TH13-07-0566","volume":"111","author":"M Konieczynska","year":"2014","unstructured":"Konieczynska M, Fil K, Bazanek M, Undas A. Prolonged duration of type 2 diabetes is associated with increased thrombin generation, prothrombotic fibrin clot phenotype and impaired fibrinolysis. Thromb Haemost. 2014;111:685\u201393. https:\/\/doi.org\/10.1160\/TH13-07-0566.","journal-title":"Thromb Haemost"},{"key":"1905_CR23","doi-asserted-by":"crossref","unstructured":"Stepie\u0144 E, Plicner D, Branicka A, Stankiewicz E, Pazdan A, Sniezek-Maciejewska M et al. Factors influencing thrombin generation measured as thrombin-antithrombin complexes levels and using calibrated automated thrombogram in patients with advanced coronary artery disease. Pol Arch Int Med, 2007;117.","DOI":"10.20452\/pamw.162"},{"key":"1905_CR24","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/eurheartj\/ehy462","volume":"40","author":"K Thygesen","year":"2019","unstructured":"Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth universal definition of myocardial infarction (2018). Eur Heart J. 2019;40:237\u201369. https:\/\/doi.org\/10.1093\/eurheartj\/ehy462.","journal-title":"Eur Heart J"},{"key":"1905_CR25","doi-asserted-by":"publisher","unstructured":"Sacco RL, Kasner SE, Broderick JP, Caplan LR, Connors JJ (Buddy), Culebras A An Updated Definition of Stroke for the 21st Century, et al. editors. Stroke 2013;44:2064\u201389. https:\/\/doi.org\/10.1161\/STR.0b013e318296aeca.","DOI":"10.1161\/STR.0b013e318296aeca"},{"key":"1905_CR26","doi-asserted-by":"publisher","first-page":"e011295","DOI":"10.1161\/JAHA.118.011295","volume":"8","author":"S Raghavan","year":"2019","unstructured":"Raghavan S, Vassy JL, Ho Y, Song RJ, Gagnon DR, Cho K, et al. Diabetes Mellitus\u2013Related all-cause and Cardiovascular Mortality in a national cohort of adults. J Am Heart Association. 2019;8:e011295. https:\/\/doi.org\/10.1161\/JAHA.118.011295.","journal-title":"J Am Heart Association"},{"key":"1905_CR27","doi-asserted-by":"publisher","unstructured":"De Caterina R, Prisco D, Eikelboom JW. Factor XI inhibitors: cardiovascular perspectives. Eur Heart J. 2022;ehac464. https:\/\/doi.org\/10.1093\/eurheartj\/ehac464.","DOI":"10.1093\/eurheartj\/ehac464"},{"key":"1905_CR28","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41569-018-0080-2","volume":"16","author":"G Patti","year":"2019","unstructured":"Patti G, Cavallari I, Andreotti F, Calabr\u00f2 P, Cirillo P, Denas G, et al. Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs. Nat Rev Cardiol. 2019;16:113\u201330. https:\/\/doi.org\/10.1038\/s41569-018-0080-2.","journal-title":"Nat Rev Cardiol"},{"key":"1905_CR29","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/j.1365-2362.1982.tb02237.x","volume":"12","author":"GM Patrassi","year":"1982","unstructured":"Patrassi GM, Vettor R, Padovan D, Girolami A. Contact phase of blood coagulation in diabetes mellitus. Eur J Clin Invest. 1982;12:307\u201311. https:\/\/doi.org\/10.1111\/j.1365-2362.1982.tb02237.x.","journal-title":"Eur J Clin Invest"},{"key":"1905_CR30","doi-asserted-by":"publisher","unstructured":"Tarumi T, Kravtsov DV, Zhao M, Williams SM, Gailani D. Cloning and characterization of the human factor XI gene promoter: transcription factor hepatocyte nuclear factor 4alpha (HNF-4alpha) is required for hepatocyte-specific expression of factor XI. J Biol Chem 2002 May 24;277(21):18510\u20136. https:\/\/doi.org\/10.1074\/jbc.M201886200.","DOI":"10.1074\/jbc.M201886200"},{"key":"1905_CR31","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1097\/MBC.0b013e32834ee194","volume":"23","author":"M Z\u0105bczyk","year":"2012","unstructured":"Z\u0105bczyk M, Butenas S, Plicner D, Fijorek K, Sadowski J, Undas A. Factors associated with the presence of circulating active tissue factor and activated factor XI in stable angina patients. Blood Coagul Fibrinolysis. 2012;23:189\u201394. https:\/\/doi.org\/10.1097\/MBC.0b013e32834ee194.","journal-title":"Blood Coagul Fibrinolysis"},{"key":"1905_CR32","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1111\/jth.14573","volume":"17","author":"FA van der Toorn","year":"2019","unstructured":"van der Toorn FA, de Mutsert R, Lijfering WM, Rosendaal FR, van Hylckama Vlieg A. Glucose metabolism affects coagulation factors: the NEO study. J Thromb Haemost. 2019;17:1886\u201397. https:\/\/doi.org\/10.1111\/jth.14573.","journal-title":"J Thromb Haemost"},{"key":"1905_CR33","doi-asserted-by":"publisher","first-page":"107153","DOI":"10.1016\/j.vph.2023.107153","volume":"149","author":"K St\u0119pie\u0144","year":"2023","unstructured":"St\u0119pie\u0144 K, Siudut J, Konieczy\u0144ska M, Nowak K, Zalewski J, Undas A. Effect of high-dose statin therapy on coagulation factors: lowering of factor XI as a modifier of fibrin clot properties in coronary artery disease. Vascul Pharmacol. 2023;149:107153. https:\/\/doi.org\/10.1016\/j.vph.2023.107153.","journal-title":"Vascul Pharmacol"},{"key":"1905_CR34","doi-asserted-by":"publisher","unstructured":"Borne PAV dem, Bajzar L, Meijers JC, Nesheim ME, Bouma BN. Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis. J Clin Invest 1997;99:2323\u20137. https:\/\/doi.org\/10.1172\/JCI119412.","DOI":"10.1172\/JCI119412"},{"key":"1905_CR35","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1111\/jth.13342","volume":"14","author":"M Colucci","year":"2016","unstructured":"Colucci M, Incampo F, Cannav\u00f2 A, Menegatti M, Siboni SM, Zaccaria F, et al. Reduced fibrinolytic resistance in patients with factor XI deficiency. Evidence of a thrombin-independent impairment of the thrombin-activatable fibrinolysis inhibitor pathway. J Thromb Haemost. 2016;14:1603\u201314. https:\/\/doi.org\/10.1111\/jth.13342.","journal-title":"J Thromb Haemost"},{"key":"1905_CR36","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.thromres.2017.10.008","volume":"161","author":"BM Mohammed","year":"2018","unstructured":"Mohammed BM, Matafonov A, Ivanov I, Sun M, Cheng Q, Dickeson SK, et al. An update on factor XI structure and function. Thromb Res. 2018;161:94\u2013105. https:\/\/doi.org\/10.1016\/j.thromres.2017.10.008.","journal-title":"Thromb Res"},{"key":"1905_CR37","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.blre.2006.11.001","volume":"21","author":"AS Wolberg","year":"2007","unstructured":"Wolberg AS. Thrombin generation and fibrin clot structure. Blood Rev. 2007;21:131\u201342. https:\/\/doi.org\/10.1016\/j.blre.2006.11.001.","journal-title":"Blood Rev"},{"key":"1905_CR38","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1055\/s-0037-1616203","volume":"86","author":"PN Walsh","year":"2001","unstructured":"Walsh PN. Roles of platelets and factor XI in the initiation of blood coagulation by thrombin. Thromb Haemost. 2001;86:75\u201382.","journal-title":"Thromb Haemost"},{"key":"1905_CR39","doi-asserted-by":"publisher","first-page":"k2693","DOI":"10.1136\/bmj.k2693","volume":"362","author":"A Douros","year":"2018","unstructured":"Douros A, Dell\u2019Aniello S, Yu OHY, Filion KB, Azoulay L, Suissa S. Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study. BMJ. 2018;362:k2693. https:\/\/doi.org\/10.1136\/bmj.k2693.","journal-title":"BMJ"},{"key":"1905_CR40","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S2213-8587(18)30315-2","volume":"7","author":"International Hypoglycaemia Study Group","year":"2019","unstructured":"International Hypoglycaemia Study Group. Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management. Lancet Diabetes Endocrinol. 2019;7:385\u201396. https:\/\/doi.org\/10.1016\/S2213-8587(18)30315-2.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1905_CR41","doi-asserted-by":"publisher","first-page":"9761","DOI":"10.1038\/s41598-022-13174-5","volume":"12","author":"A Pallares Robles","year":"2022","unstructured":"Pallares Robles A, Ten Cate V, Schulz A, Prochaska JH, Rapp S, Koeck T, et al. Association of FXI activity with thrombo-inflammation, extracellular matrix, lipid metabolism and apoptosis in venous thrombosis. Sci Rep. 2022;12:9761. https:\/\/doi.org\/10.1038\/s41598-022-13174-5.","journal-title":"Sci Rep"},{"key":"1905_CR42","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.33963\/KP.a2022.0282","volume":"80","author":"M We\u0142nicki","year":"2022","unstructured":"We\u0142nicki M, Gorczyca-G\u0142owacka I, Mamcarz A, Filipiak KJ, Wo\u017cakowska-Kap\u0142on B, Barylski M, et al. The use of GLP-1 analogues in the treatment of diabetes in patients with cardiovascular diseases. The expert opinion of the Working Group of Cardiovascular Pharmacotherapy of the polish Cardiac Society. Kardiol Pol (Polish Heart Journal). 2022;80:1286\u20139. https:\/\/doi.org\/10.33963\/KP.a2022.0282.","journal-title":"Kardiol Pol (Polish Heart Journal)"},{"key":"1905_CR43","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.33963\/KP.a2022.0283","volume":"80","author":"S Carlin","year":"2022","unstructured":"Carlin S, de Vries TAC, Budaj A, Eikelboom J. Dual pathway inhibition for atherosclerotic cardiovascular disease: recent advances. Kardiol Pol (Polish Heart Journal). 2022;80:1200\u201310. https:\/\/doi.org\/10.33963\/KP.a2022.0283.","journal-title":"Kardiol Pol (Polish Heart Journal)"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-023-01905-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-023-01905-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-023-01905-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T18:03:48Z","timestamp":1689617028000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-023-01905-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,17]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1905"],"URL":"https:\/\/doi.org\/10.1186\/s12933-023-01905-5","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,17]]},"assertion":[{"value":"12 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the local ethics committee. Study participants provided informed written consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflict of interest to declare with regard to this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"182"}}